Business, energy, technology, markets and global industry news from Business News Today

Roche Diagnostics

PharmaDeviceNews Roche Diagnostics
Alzheimer’s blood tests are moving into clinical practice as biomarkers such as phosphorylated tau improve diagnostic accuracy, but assay differences and laboratory quality could determine how widely the technology is trusted. Representative image.
Features & Analysis

A blood test changed one-third of doctors’ Alzheimer’s diagnoses. Is routine screening the next step?

Alzheimer’s blood tests are moving from specialist research into clinical practice after real-world evidence showed that biomarker results sharply improved diagnostic accuracy. The opportunity is substantial, but differences between assays, inappropriate screening and laboratory-quality failures could undermine confidence.

Read More
AstraZeneca’s investigational CLDN18.2 antibody-drug conjugate sonesitatug vedotin improved overall survival in a Phase 3 trial involving previously treated advanced gastric and gastroesophageal junction cancers, although the progression-free survival endpoint was not statistically significant. Representative image.
Pharma & Biotech

Sonesitatug vedotin Phase 3 survival win strengthens AstraZeneca’s gastric cancer ADC strategy

Read why AstraZeneca’s sonesitatug vedotin survival win in CLDN18.2-positive gastric cancer is tempered by a Phase 3 PFS miss.

Read More
FDA clears Roche cobas BV/CV PCR assay for symptomatic vaginitis diagnosis
Medical Devices & Diagnostics

Roche’s new vaginitis PCR test is FDA-cleared, but the real commercial test starts inside laboratories

Roche’s cobas BV/CV assay gains FDA clearance for combined BV and Candida testing, setting up a 2026 U.S. laboratory launch.

Read More
Representative image: A pathology specialist reviews PTEN biomarker staining as NeoGenomics launches an FDA-approved companion diagnostic to identify prostate cancer patients who may be eligible for AstraZeneca’s Truqap.
Medical Devices & Diagnostics

How the NeoGenomics PTEN IHC test supports targeted prostate cancer treatment

NeoGenomics launches an FDA-approved PTEN IHC companion diagnostic to identify prostate cancer patients eligible for AstraZeneca’s Truqap.

Read More
Representative image: Targeted prostate cancer treatment enters focus as AstraZeneca’s Truqap approval highlights PTEN-deficient metastatic disease, biomarker testing, and the future of precision oncology.
Medical Devices & Diagnostics

Why AstraZeneca’s Truqap win could force a new testing era in prostate cancer

Find out how AstraZeneca’s Truqap approval could reshape PTEN-deficient prostate cancer treatment and biomarker testing.

Read More
Representative image: Roche’s $1.05bn PathAI acquisition highlights how AI-powered digital pathology could accelerate tissue analysis, companion diagnostics, and precision oncology workflows across modern diagnostics laboratories.
Medical Devices & Diagnostics

What Roche’s $1.05bn PathAI move reveals about the future of pathology labs

Roche wants AI pathology at scale. PathAI gives it the tissue-analysis layer needed to tighten diagnostics, trials, and precision oncology.

Read More